Studying the Role of Novel Carbon Nano Tubes as a Therapeutic Agent to Treat Triple Negative Breast Cancer (TNBC) - an In Vitro and In Vivo Study

Authors

  • Kamal Asadipour Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA-23529, USA
  • Narendra Banerjee Department of Natural Sciences, Pharmaceutical and Health Sciences, Elizabeth City State University Campus of The University of North Carolina, Elizabeth City, NC 27909, USA
  • Jazmine Cuffee Department of Natural Sciences, Pharmaceutical and Health Sciences, Elizabeth City State University Campus of The University of North Carolina, Elizabeth City, NC 27909, USA
  • Karrington Perry Department of Natural Sciences, Pharmaceutical and Health Sciences, Elizabeth City State University Campus of The University of North Carolina, Elizabeth City, NC 27909, USA
  • Shennel Brown Department of Natural Sciences, Pharmaceutical and Health Sciences, Elizabeth City State University Campus of The University of North Carolina, Elizabeth City, NC 27909, USA
  • Anasua Banerjee Department of Cell Biology, Harvard University, Boston, MA-02115, USA
  • Erik Armstrong Department of Natural Sciences, Pharmaceutical and Health Sciences, Elizabeth City State University Campus of The University of North Carolina, Elizabeth City, NC 27909, USA
  • Stephen Beebe Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA-23529, USA
  • Hirendra Banerjee Department of Natural Sciences, Pharmaceutical and Health Sciences, Elizabeth City State University Campus of The University of North Carolina, Elizabeth City, NC 27909, USA https://orcid.org/0000-0002-1836-1731

DOI:

https://doi.org/10.30683/1929-2279.2024.13.06

Keywords:

Carbon Nano Tube, Triple Negative Breast Cancer, Epithelial Mesenchymal Transition, Spheroids, Nanotechnology, Theragnostic

Abstract

Triple Negative Breast Cancer (TNBC) is a malignant cancer with a very high mortality rate around the world. African American(AA) women are 28% more likely to die from triple-negative breast cancer (TNBC) than white women with the same diagnosis. AA patients are also more likely to be diagnosed at a later stage of the disease and have the lowest survival rates for any stage of diagnosis; There are very few existing anti TNBC drugs with therapeutic efficacy hence newer anti TNBC drug design and investigation is needed. Carbon Nano Tubes(CNT) in recent years have shown effective anti-cancer properties in various types of cancers as reported in peer reviewed journals. Henceforth, we did an investigation to study the anticancer properties of a novel CNT in both in vitro and in vivo models of TNBC. We tested the CNT drug in vitro cytotoxicity studies on TNBC model MDA-MB-231 VIM RFP cell lines and Spheroid forming assays on the same cancer cells; we also did an in vivo study on TNBC model mice to study the therapeutic efficacy of this CNT drug in reducing the tumor load. Our initial studies showed increased cell death and reduction in spheroid numbers in the CNT treated cancer cells in comparison to control and a significant reduction in the tumor volume in the TNBC model mice than in untreated animals. Thus our initial studies have shown significant therapeutic efficacy of the novel CNT as an anti TNBC agent. Additional mechanistic studies need to be done to find out the cell death mechanisms, core canonical pathways involved, pharmacokinetic studies before translational research for this novel nanoparticle as a therapeutic agent from bench to bedside.

References

Srivastava N, Mishra Y, Mishra V, Ranjan A, Tambuwala MM. Carbon Nanotubes in Breast Cancer Treatment: An Insight into Properties, Functionalization, and Toxicity. Anticancer Agents Med Chem 2023; 23(14): 1606-1617. https://doi.org/10.2174/1871520623666230510094850

Ahmadian E, Janas D, Eftekhari A, Zare N. Application of carbon nanotubes in sensing/monitoring of pancreas and liver cancer. Chemosphere 2022; 302: 134826. https://doi.org/10.1016/j.chemosphere.2022.134826

Banerjee HN, Verma M. Application of nanotechnology in cancer. Technol Cancer Res Treat 2008; 7(2): 149-54. https://doi.org/10.1177/153303460800700208

Panigrahi BK, Nayak AK. Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics. Curr Drug Deliv. 2020; 17(7): 558-576. https://doi.org/10.2174/1567201817999200508092821

Faraji Dizaji B, Khoshbakht S, Farboudi A, Azarbaijan MH, Irani M. Far-reaching advances in the role of carbon nanotubes in cancer therapy. Life Sci 2020; 257: 118059. https://doi.org/10.1016/j.lfs.2020.118059

Banerjee H, Joyner J, Stevenson M, Kaha W, Krauss C, Hodges S, Santos E, Worthington M, Rousch J, Payne G, Manglik V, Banerjee N, Morris B, Bell D, Mandal S. Short Communication: Studying the Role of Smart Flare Gold Nano Particles in Studying Micro RNA and Oncogene Differential Expression in Prostate Cancer Cell Lines. J Can Res Updates 2017; 6(2): 25-28. https://doi.org/10.6000/1929-2279.2017.06.02.1

Ji SR, Liu C, Zhang B, Yang F, Xu J, Long J, Jin C, Fu DL, Ni QX, Yu XJ. Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta 2010; 1806(1): 29-35. https://doi.org/10.1016/j.bbcan.2010.02.004

Radzi MRM, Johari NA, Zawawi WFAWM, Zawawi NA, Latiff NA, Malek NANN, Wahab AA, Salim MI, Jemon K. In vivo evaluation of oxidized multiwalled-carbon nanotubes-mediated hyperthermia treatment for breast cancer. Biomater Adv 2022; 134: 112586. https://doi.org/10.1016/j.msec.2021.112586

Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 2020; 22(1): 61. https://doi.org/10.1186/s13058-020-01296-5

Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 2022; 15(1): 121. https://doi.org/10.1186/s13045-022-01341-0

Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov 2019; 9(2): 176-198. https://doi.org/10.1158/2159-8290.CD-18-1177

Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer 2023; 22(1): 145. https://doi.org/10.1186/s12943-023-01850-7

Erratum in: Mol Cancer 2023; 22(1): 154. https://doi.org/10.1186/s12943-023-01858-z

Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, Park DW, Park J, Jeang JW, Kang SC. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol 2023; 212: 115545. https://doi.org/10.1016/j.bcp.2023.115545

Keenan TE, Tolaney SM. Role of Immunotherapy in Triple-Negative Breast Cancer. J Natl Compr Canc Netw 2020; 18(4): 479-489. https://doi.org/10.6004/jnccn.2020.7554

Vagia E, Mahalingam D, Cristofanilli M. The Landscape of Targeted Therapies in TNBC. Cancers (Basel) 2020; 12(4): 916. https://doi.org/10.3390/cancers12040916

Cho AA, Bonavida B. Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis. Crit Rev Oncog 2017; 22(1-2): 49-61. https://doi.org/10.1615/CritRevOncog.2017020473

Si L, Yang Z, Ding L, Zhang D. Regulatory effects of lncRNAs and miRNAs on the crosstalk between autophagy and EMT in cancer: a new era for cancer treatment. J Cancer Res Clin Oncol 2022; 148(3): 547-564. https://doi.org/10.1007/s00432-021-03892-0

Jin W. Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition. Cells 2020; 9(1): 217. https://doi.org/10.3390/cells9010217

Cagle E, Lake B, Banerjee A, Cuffee J, Banerjee N, Gilmartin D, Liverman M, Brown S, Armstrong E, Bhattacharya S, Ghosh S, Mandal T, Banerjee H. Analysis of Differential Gene Expression and Core Canonical Pathways Involved in the Epithelial to Mesenchymal Transition of Triple Negative Breast Cancer Cells by Ingenuity Pathway Analysis. Comput Mol Biosci 2023; 13(2): 21-34. https://doi.org/10.4236/cmb.2023.132002

Murugesan R, Raman S. Recent Trends in Carbon Nanotubes Based Prostate Cancer Therapy: A Biomedical Hybrid for Diagnosis and Treatment. Curr Drug Deliv 2022; 19(2): 229-237. https://doi.org/10.2174/1567201818666210224101456

Hassan HAFM, Diebold SS, Smyth LA, Walters AA, Lombardi G, Al-Jamal KT. Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances. J Control Release 2019; 297: 79-90. https://doi.org/10.1016/j.jconrel.2019.01.017

Al Garalleh H. Fullerene Derivatives (CN-[OH]β) and Single-Walled Carbon Nanotubes Modelled as Transporters for Doxorubicin Drug in Cancer Therapy. Int J Mol Sci 2022; 23(17): 9646. https://doi.org/10.3390/ijms23179646

Guo Q, Shen XT, Li YY, Xu SQ. Carbon nanotubes-based drug delivery to cancer and brain. J Huazhong Univ Sci Technolog Med Sci 2017; 37(5): 635-641. https://doi.org/10.1007/s11596-017-1783-z

Banerjee HN, Verma M. Use of nanotechnology for the development of novel cancer biomarkers. Expert Rev Mol Diagn 2006; 6(5): 679-83. https://doi.org/10.1586/14737159.6.5.679

Zhang Y, Li M, Gao X, Chen Y, Liu T. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J Hematol Oncol 2019; 12(1): 137. https://doi.org/10.1186/s13045-019-0833-3

Meng J, Yang M, Jia F, Xu Z, Kong H, Xu H. Immune responses of BALB/c mice to subcutaneously injected multi-walled carbon nanotubes. Nanotoxicology 2011; 5(4): 583-591. https://doi.org/10.3109/17435390.2010.523483

Downloads

Published

2024-11-11

How to Cite

Asadipour, K. ., Banerjee, N. ., Cuffee, J. ., Perry, K. ., Brown, S. ., Banerjee, A. ., Armstrong, E. ., Beebe, S. ., & Banerjee, H. . (2024). Studying the Role of Novel Carbon Nano Tubes as a Therapeutic Agent to Treat Triple Negative Breast Cancer (TNBC) - an In Vitro and In Vivo Study. Journal of Cancer Research Updates, 13, 37–41. https://doi.org/10.30683/1929-2279.2024.13.06

Issue

Section

Articles